Notably, high POLR3G expression is associated with poor survival outcomes in a variety of cancers, including transitional cell carcinoma [14], multiple myeloma [15], hepatocellular carcinoma [16], and lung adenocarcinoma [17]. Here, POLR3G is linked to plasma cell myeloma.